RATIONALE FOR A COMPASSION WAIVER FOR STEM CELL THERAPY FOR END STAGE CONGESTIVE HEART FAILURE PATIENTS
Statement by Christian Wilde
It is statistically estimated that 22M patients are currently dying worldwide of congestive heart failure. Medicine’s mantra to do no harm in cases of late stage heart failure may actually be counterproductive, permitting even more harm, (the very result medicine strives to avoid) by restricting stem cell intervention for advanced heart failure patients. A substantial argument may be made that by not offering this population of 7.5 year life expectancy patients, the positive benefits already documented and witnessed in ongoing stem cell heart failure trials in the US and elsewhere, patients may be deprived of a viable opportunity to prolong their lives. It may be well to ask, if wanting to do no harm is the objective, then how harmful in fact, is doing nothing?
In terms of both human tragedy and a 39.2B financial burden to the US healthcare system annually, why should it not be acceptable, based on the already documented results of adult stem cell skeletal myoblast and bone marrow cell transplants to intervene on behalf of patients? In so doing, giving families the fighting chance and benefit as already evidenced and documented in numerous trials? Modern science admittedly has limitations for treatment for advanced heart failure patients and currently absorbs the expense associated with 800,000 yearly hospital admissions and readmissions to stabilize late disease as many “no option” patients face a dire prognosis. What could be the rationale of not permitting this population of patients to receive stem cell therapy? Where is the risk to the late stage patient? To not permit these patients and their families this chance is counter to everything medicine seeks to accomplish in patient care. It may be argued that the probability of extending life may be more probable with this disease than with any stem cell therapy to date.
Christian Wilde is an author/reseacher whose work has been endorsed or contributed to by directors of Preventive Cardiology and Cardiovascular Stem Cell Therapy at 11 major universities. He is the first to advise that you should discuss all supplements with your physician before embarking on adjunct or replacement therapy as your physician is your ultimate health advisor who best knows your particular case. Therefore the information you obtain from the author's books and news reports is not meant to treat or replace your current therapies but to inform you as to what is available or becoming available in the research community generally years ahead of the practicing physician's office.
